Self-Administered, Subcutaneous Alemtuzumab to Treat Residual Disease in Patients With Chronic Lymphocytic Leukemia

BACKGROUND: Alemtuzumab is highly effective at treating chronic lymphocytic leukemia (CLL) in bone marrow, which is the usual site of residual disease after fludarabine-based treatment. Eliminating residual disease potentially is associated with longer remission and overall survival. The authors of...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Cancer
Main Authors: Wierda, William G., Kipps, Thomas J., Keating, Michael J., Brown, Jennifer R., Gribben, John G., Browning, Mary, Rassenti, Laura Z., Greaves, Andrew W., Neuberg, Donna, O’Brien, Susan M.
Format: Artigo
Sprog:Inglês
Udgivet: 2010
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4535917/
https://ncbi.nlm.nih.gov/pubmed/20806349
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.25379
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker